This is a multicenter, ambispective observational cohort study. The patients with coronavirus disease 2019 (COVID-19) will be included in the study. The patients will be dividedinto 4 groups according to the treatment mode (Azvudine treatment group within 48 hoursafter the first positive for nucleic acid, Azvudine treatment group after 48 hours afterthe first positive for nucleic acid, short course of Azvudine treatment without nucleicacid turning negative, and the control group) . This study aims to analyze the efficacyand safety of Azvudine in the treatment of patients with COVID-19.
Not Provided
Drug: Azvudine
Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in
the Diagnostic and therapeutic protocol for COVID-9 in China.
Inclusion Criteria:
- Patients with confirmed diagnosis of COVID-19 pneumonia
- Patients with the ability to take medication orally
Exclusion Criteria:
- Severe vomiting and difficulty in taking oral medication or ingestion of drugs after
oral administration
- Suspected or confirmed active systemic infection other than COVID-19 pneumonia
- Pregnant or lactating women
- Patients with mental disorders
- Patients with severe liver damage
- Patients who are treated with small molecule drugs such as Nirmatrelvir
Tablets/Ritonavir Tablets(co-packaged)
- Patients who are treated with RNA-dependent RNA polymerase (RDRP) inhibitors
(Junshipharma VV116, Ascletis Pharma Inc. Asc10, Kexing biopharm Shen26, and
Molnupiravir).
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, China
Investigator: Qian Qi, Dr.
Contact: +86 13706380314
qiqianqlh@163.com
Qian Qi, Dr.
+86 13706380314
qiqianqlh@163.com
Not Provided